Canaccord lowered the firm’s price target on iRhythm (IRTC) to $125 from $137 and keeps a Buy rating on the shares. The firm said they reported a solid Q3/24 and gave guidance in-line with expectations but they lowered their target to reflect both lower comp group multiples and slightly lower 2025 revenue due to the pushout of ZioMCT.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC: